miRNA 作为癫痫生物标志物的挑战。
The Challenge of microRNA as a Biomarker of Epilepsy.
机构信息
Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
Curr Neuropharmacol. 2018;16(1):37-42. doi: 10.2174/1570159X15666170703102410.
BACKGROUND
Epilepsy is one of chronic severe neurological disorders possess to recurring seizures. And now anti-epileptic drugs are only effective in less than one third of epilepsy patients, and biomarkers predicting are not available when the specific antiepileptic drugs treated. Advanced studies have showed that miRNA may be a key in the pathogenesis of epilepsy beginning in the early 2000 years. Several target genes and pathways of miRNA which related to the therapeutic methods to epilepsy.
METHOD
We searched PubMed from Jan 1,2000 to Jan 1, 2017, using the terms "epilepsy AND microRNA AND biomarker" and "seizure AND microRNA AND biomarker". We selected articles that featured novel miRNAs in vivo epilepsy models and patients. We then selected the most relevant articles based on a subjective appraisal of their quality and mechanistic insight that could be relevant to epilepsy.
RESULTS
Decrease the expression of has-miR134 could be a potential non-invasive biomarker to use in diagnosis for the epilepsy patients for using hsa-miR-134 also be identified to distinguish patients with and without epilepsy. miR-181a show significant downregulation in the acute stage, but up regulation in the chronic stage and in the latent stage there is no changing and how about this phenomenon appearance in different stage still should be discussed in the future. Besides that, miR- 146a can down-regulated in the patients using genome-wide for serum in circulating miRNAs.miR- 124, miR-199a, and miR-128 etc. could be a candidate for the biomarker in future. miR-15a-5p and -194-5p down-regulated in epilepsy patients, in the future, it may be used as a novel biomarker for improve diagnosis.
CONCLUSION
These observations give a chance that new development for diagnosis and treatment of epilepsy patients. Advanced technique and miRNA combination may product more effective roles in epilepsy and other disease. These reports will be available to solve the application of miRNAs as biomarkers and novel therapy approaches for epilepsy. In summary, researcher who focus on miRNAs should be understanding of the causes, treatment, and diagnosis of epilepsy. exploration of any of these effects on the efficacy of these drugs is worthwhile.
背景
癫痫是一种慢性严重的神经系统疾病，表现为反复发作。目前，抗癫痫药物仅对三分之一的癫痫患者有效，当使用特定的抗癫痫药物治疗时，也没有可预测的生物标志物。早在 21 世纪初，高级研究就表明 miRNA 可能是癫痫发病机制中的一个关键因素。miRNA 的几个靶基因和途径与癫痫的治疗方法有关。
方法
我们从 2000 年 1 月 1 日到 2017 年 1 月 1 日在 PubMed 上进行了搜索，使用的术语是“癫痫 AND microRNA AND 生物标志物”和“癫痫 AND microRNA AND 生物标志物”。我们选择了那些在体内癫痫模型和患者中具有新型 miRNA 的文章。然后，我们根据对其质量和对癫痫相关机制的深入了解的主观评估，选择了最相关的文章。
结果
hsa-miR-134 的表达降低可能是癫痫患者诊断的潜在非侵入性生物标志物，也可以使用 hsa-miR-134 来区分癫痫患者和非癫痫患者。miR-181a 在急性期显著下调，但在慢性期和潜伏期上调，在不同阶段出现这种现象的原因仍有待进一步讨论。此外，在全基因组血清循环 miRNAs 中，miR-146a 可以下调。miR-124、miR-199a 和 miR-128 等可能成为未来的生物标志物候选物。miR-15a-5p 和 -194-5p 在癫痫患者中下调，将来可能作为一种新的诊断标志物。
结论
这些观察结果为癫痫患者的诊断和治疗提供了新的发展机会。先进的技术和 miRNA 的结合可能在癫痫和其他疾病中发挥更有效的作用。这些报告将有助于解决 miRNA 作为生物标志物和治疗癫痫的新方法的应用问题。总之，关注 miRNA 的研究人员应该了解癫痫的病因、治疗和诊断。探索这些药物的任何影响都值得关注。
Zotero 插件